KOSPIBiotech & Pharma0126Z0

Samsung Epis Holdings

₩366,500▼ 1.87%2026-10-02 close

Market Cap

₩9.1T

Turnover

₩9.4B

Volume

30,000 shares

Shares out.

24.9M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Biosimilar Powerhouse Pivots to Novel Drug Development

Established in November 2025 through a spin-off from Samsung BioLogics, Samsung Epis Holdings is leveraging subsidiary Samsung Bioepis's market-leading European biosimilar portfolio to fund an emerging ADC and novel drug pipeline, pursuing a 'Korean Big Pharma' growth model.

1
World's largest European antibody biosimilar portfolio: expanded to 10 commercialized products in early 2026, maintaining lead over domestic rival Celltrion (8 products)
2
FY2025 record revenue of KRW 1.6720 trillion (+9% YoY); ex-milestone product sales up 28% with operating profit surging 101%, reflecting strong underlying commercial momentum
3
ADC drug candidate SBE303 received FDA IND approval in March 2026 and entered Phase 1 trials; pipeline diversification into obesity and oncology treatments is underway
4
Biosimilars exempted from U.S. tariff measures targeting branded drugs, creating a favorable pricing dynamic vs. originator products in the American market
5
Accounting noise from post-split PPA amortization and holding company overhead costs warrants a careful separation from underlying cash flow performance

Business structure

Samsung Epis Holdings is a biotech holding company spun off from Samsung BioLogics in November 2025, operating the global biosimilar business through its wholly-owned subsidiary Samsung Bioepis.

The holding company's largest shareholder is Samsung C&T (43.06%), with Samsung Electronics holding 31.22%, positioning the entity as a central R&D pillar within the Samsung Group's biopharma value chain.

Samsung Bioepis has successfully developed a world-record 11 antibody biosimilar products across autoimmune, rare disease, ophthalmology, and bone disease indications, distributing them in over 40 countries; as of early 2026, it commercializes 10 products in Europe alone—more than any other antibody biosimilar developer globally.

Approximately 60% of revenues originate from Europe, underpinned by co-commercialization partnerships with Biogen (BIIB) and Teva (TEVA).

The company is actively expanding its direct-sales model: following the direct-sale launch of Epizcly (Soliris biosimilar), it introduced bone disease products Obodens and Xbrik under direct sales in early 2026, aiming to internalize distribution margins and improve profitability.

Newly established subsidiary EpisNexLab is dedicated to next-generation modality platforms including bispecific antibodies and peptide drugs, with co-development rights secured from China's Frontline Biopharma and a joint obesity R&D partnership (including a KRW 20 billion CB investment by Samsung Epis Holdings) with G2G Bio.

Domestic rival Celltrion is intensifying competition with eight European products and a U.S. manufacturing base, but Samsung Bioepis retains leadership in European antibody biosimilar product count.

The company targets 20 biosimilar products by 2030, with seven additional next-generation blockbusters—including Keytruda, Dupixent, Enhertu, Tremfya, Taltz, Entyvio, and Ocrevus—in active biosimilar development.

Funding novel drug investment from biosimilar cash flows represents the defining strategic direction: a 'cash-generative R&D pivot' model.

Recent trends

Per public disclosures in April 2026, Samsung Bioepis reported FY2025 annual revenue of KRW 1.6720 trillion—a new all-time high—up 9% (KRW 134.3 billion) year-on-year.

Operating profit came in at KRW 375.9 billion, declining 14% YoY due to the high milestone income base from 2024; on an ex-milestone product-sales basis, however, revenue grew 28% and operating profit surged 101%, reflecting robust underlying commercial momentum.

In Q1 2026, Samsung Bioepis recorded revenue of KRW 454.9 billion (+13.6% YoY) and operating profit of KRW 144.0 billion (+12.6% YoY), sustaining double-digit growth.

Samsung Epis Holdings' first consolidated results as an independent holding company (covering November–December 2025, two months) showed revenue of KRW 251.7 billion and an operating loss of KRW 63.6 billion; management attributed this loss to non-cash PPA amortization and increased R&D costs from the corporate split, noting no impact on actual cash flows.

On the stock front, shares fell approximately 28% on the first trading day (November 24, 2025) to KRW 438,500 but subsequently rebounded sharply to KRW 712,000 by mid-December, recording a 52-week high of KRW 773,000.

The stock has since retraced to KRW 453,000 as of June 4, 2026—approximately 41% below its 52-week peak—reflecting sector-wide volatility and ongoing holding company discount concerns.

For FY2026, management has officially guided for revenue growth of 10%+, with U.S. market penetration by Stelara and Soliris biosimilars and expanded European direct sales cited as the key growth catalysts.

Outlook

The global biosimilar market is entering a structural growth supercycle, with approximately USD 220 billion in blockbuster drug patent expirations expected between 2025 and 2029; the European market is projected to grow at roughly 35% CAGR through 2030.

Samsung Bioepis is well-positioned as a direct beneficiary through its European market leadership and U.S. PBM private-label strategy, with European direct-sales products expanding to three in 2026, supporting a gradual improvement in margin structure via distribution margin internalization.

The U.S. tariff framework's exemption of biosimilars from the high tariffs imposed on patented drugs creates a favorable pricing dynamic, adding a medium-term tailwind to American revenue growth.

On the novel drug front, ADC candidate SBE303 received FDA IND approval in March 2026 and entered Phase 1 trials, with management targeting at least one new clinical-stage NDA annually from 2027 onward.

Seven next-generation blockbuster biosimilars in active development make the 20-product target for 2030 increasingly credible.

However, the dissipation of milestone income and rising holding company overhead may constrain near-term profit visibility, and years of clinical validation are needed before novel drug pipeline value can be meaningfully incorporated into valuations. FDA development guideline simplification and the U.S.

Biosecure Act restricting Chinese biotech competitors represent additional medium-to-long-term structural tailwinds.

Bull factors

Biosimilar Supercycle Meets Direct-Sales Shift

The biosimilar supercycle—driven by approximately USD 220 billion in blockbuster patent expirations from 2025 to 2029—positions Samsung Bioepis as a structural growth beneficiary, backed by its market-leading 10-product European portfolio.

Direct-sale products are expanding to three in Europe in 2026, while PBM private-label agreements in the U.S. are accelerating early market penetration for the Stelara biosimilar, supporting gradual margin improvement.

With Q1 2026 subsidiary revenue growing 13.6% YoY, the growth trajectory remains intact, and the earnings leverage potential once direct-sales contributions fully reflect is noteworthy.

ADC and Novel Drug Pipeline Option Value

Following the corporate split, Samsung Epis Holdings has accelerated new drug development, securing FDA IND approval for ADC candidate SBE303 in March 2026 and initiating Phase 1 trials.

Rapid expansion of the novel drug ecosystem—via EpisNexLab's next-generation modality platform and the obesity drug joint R&D partnership—reinforces a growing pipeline of optionality.

If the model of funding novel drug investment from biosimilar cash flows proves sustainable, the market could begin assigning meaningful option value to the novel drug pipeline, triggering a re-rating beyond the current holding company discount.

U.S. Tariff Exemption Widens Price Advantage Over Originators

The Trump administration's April 2026 pharmaceutical tariff policy exempts biosimilars from the 100% tariff applied to patented branded drugs, relieving pressure on Korean biosimilar exporters.

Should originator companies pass tariff costs through to drug prices, the relative cost-saving appeal of biosimilars in the U.S. market could accelerate prescription penetration meaningfully.

As Samsung Bioepis's Stelara and Soliris biosimilars are still in the early stages of U.S. market penetration, this policy environment represents a significant medium-term tailwind for American revenue growth.

Bear factors

Milestone Cliff and Weakening Near-Term Profit Visibility

FY2025 operating profit declined 14% YoY due to the high milestone income base from 2024, and the structural dissipation of such one-time revenues limits operating profit growth despite continued revenue expansion.

PPA amortization totaling approximately KRW 200-300 billion spread over 10 years, combined with rising novel drug R&D expenses, adds near-term pressure on profitability.

As evidenced by the KRW 63.6 billion operating loss in the first two-month consolidated results, the holding company accounting structure introduces elevated earnings volatility that complicates near-term earnings modeling.

Long Road to Novel Drug Pipeline Value Realization

ADC candidate SBE303 only entered Phase 1 trials in March 2026, placing it at the earliest stage of clinical development, while SBE313 (co-developed with China's Frontline) remains in the preclinical phase.

Novel drug development involves significant failure risk at each clinical stage, with commercialization typically requiring more than a decade of sustained capital investment.

Even if the biosimilar-funded novel drug model proves viable, meaningful valuation uplift from the pipeline remains a medium-to-long-term prospect, and assigning a substantial premium at this juncture carries considerable uncertainty.

Intensifying Biosimilar Price Competition and Market Share Defense

Celltrion is rapidly narrowing the competitive gap with eight European products and a U.S. manufacturing base, intensifying rivalry across both key markets.

Government and PBM pressure to reduce healthcare costs is driving sustained biosimilar price erosion, which could cap profitability improvements even as revenues grow.

In particular, core product Benepali (Enbrel biosimilar) faces an increasingly crowded post-patent market, and high concentration in certain products means price pressure on these assets can translate swiftly into consolidated earnings headwinds.

Risk factors

Policy & Trade Risk

The U.S. biosimilar tariff exemption includes a one-year review clause, meaning the favorable regime could be revised or revoked on short notice; medium-term pressure to establish U.S. production facilities cannot be dismissed.

The Trump administration's escalating focus on drug price negotiations and intensifying European tender competition represent structural headwinds to medium-term price defense.

Strengthened U.S. onshoring production policies could heighten regulatory uncertainty for Samsung Bioepis's Korea-based production model, potentially disadvantaging the company relative to competitors—such as Celltrion—that already hold U.S. manufacturing assets.

Accounting & Holding Structure Risk

PPA amortization totaling approximately KRW 200-300 billion spread over 10 years will continue to weigh on consolidated earnings visibility, and the restructuring of inter-company transactions following the split may amplify consolidated results volatility.

A persistent holding company discount in market valuation could maintain a structural gap between subsidiary earnings performance and parent company share price appreciation over time.

The initial investment and operating costs of newly established subsidiaries such as EpisNexLab may add further near-term pressure to consolidated profitability.

Clinical & Pipeline Risk

Novel drug candidates, including ADC pipeline SBE303, are at Phase 1 or preclinical stages only; development failures, delays, or regulatory setbacks could significantly impair anticipated enterprise value.

On the biosimilar pipeline side, complex molecular structures and demanding regulatory requirements for next-generation blockbuster targets such as Keytruda and Dupixent carry meaningful risks of extended development timelines and cost overruns.

Clinical data disappointments or competitor pipeline approvals represent event risks that could negatively impact the stock in the near term, underscoring the need for close and ongoing pipeline monitoring.

Overall view

Samsung Epis Holdings is a structural beneficiary of the global biosimilar supercycle, backed by the world's most extensive European antibody biosimilar portfolio—a demonstrably valuable franchise.

Record FY2025 revenues and sustained double-digit growth in Q1 2026 affirm the underlying business model's resilience, while the U.S. tariff exemption and expanding direct-sales coverage provide structural mid-term margin improvement drivers.

However, near-term profit headwinds from milestone income attrition, post-split accounting noise, and the long-dated uncertainty of the novel drug pipeline complicate a definitive positive valuation call.

At KRW 453,000, shares have retraced approximately 41% from the 52-week high, suggesting much of the initial post-listing euphoria has been unwound. That said, meaningful recognition of novel drug option value requires further clinical milestones to materialize.

Key near-term monitoring indicators include FY2026 revenue guidance achievement (10%+), SBE303 Phase 1 interim data readouts, and the margin uplift from expanding direct-sales coverage in Europe.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 12 more articles and sources

Report written 2026-06-04 · Data as of 2026-06-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.